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FEARING FEAR ITSELF:
THE PROPOSED GENETIC INFORMATION
NONDISCRIMINATION ACT OF 2005 AND
PUBLIC FEARS ABOUT GENETIC
INFORMATION
Rivka Jungreis∗
“Men and women will increasingly be judged not by the
color of their skin but by the content of their
chromosomes.”1
INTRODUCTION
With the completion of the Human Genome Project in 2003,
medicine and scientific research have embarked on a new era of
possibility.2 Among the prospects to which we can look forward
as a result of this development are improved disease diagnosis
and assessment of disease susceptibility, vastly improved
∗

B.S. Interdisciplinary Sciences, Touro College, M.S. Biology, NYU
Graduate School of Arts and Sciences, J.D. Candidate 2008, Brooklyn Law
School. The author would like to thank Rabbi Jacob and Shifrah Jungreis for
their boundless support and encouragement, Yisrael Jungreis and Miriam
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process, and most of all Tzvi Hersh Jungreis for his constant devotion, love
and support. Without all of your help, this would not have been possible.
1
Andrew Sullivan, The Way We Live Now: 7-23-00: Counter Culture;
Promotion of the Fittest, N.Y. TIMES, July 23, 2000, at F16 (proposing that
in the wake of the Human Genome Project, genetic discrimination is both
rational and inevitable).
2
See The Future of Genomics: Hearing Before the Subcomm. on Health
of the H. Comm. on Energy and Commerce, 108th Cong. (2003) (statement
of Francis A. Collins, Director, National Human Genome Research Institute).
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treatment and outcomes, and the progression of scientific
research.3 Yet, along with the promise that genetic testing
shows, new genetic technologies create additional possibilities
for discrimination based on a person’s genetic makeup.4
Pursuant to this concern, numerous propositions for federal
legislative initiatives targeting genetic discrimination in health
insurance and in the workplace have appeared in Congress over
the last decade.5
This Note argues that a federal statute addressing genetic
discrimination in the workplace and in insurance underwriting is
prudent. Although the fear of genetic discrimination remains
more persistent than the discrimination itself, it is important to
address that fear, as it deters many people from undergoing
genetic testing.6 This Note also argues that educational initiatives
alone cannot accomplish a reduction of the fear in a timely
manner.
Section I provides a brief overview of genetic information
and the current state of genetic testing. Section II discusses the
occurrence of genetic discrimination in employment and in
health insurance, and Section III describes H.R. 1227, the
Genetic Information Nondiscrimination Act of 2005 (GINA),
which is the current version of proposed federal legislation
targeting such discrimination.7 Section IV sets forth a
comprehensive assessment of the desirability of passing such

3

See id.
See Genetic Discrimination in Health Insurance, What is the issue?,
http://www.genome.gov/10002328 (last visited Oct. 16, 2006).
5
Genetic Discrimination in Health Insurance, What are the legislative
protections?, http://www.genome.gov/10002328 (last visited Oct. 16, 2006)
(“Nine bills were introduced in the 106th Congress (1999-2000), and four in
the 107th Congress (2001-02).”). Five bills were introduced in the 108th
Congress (2003-04). In the current Congress, a bill was unanimously passed
in the Senate, and is pending in the House. See Federal Legislation about
Genetic Privacy, http://www.genome.gov/11510239 (last visited Oct. 16,
2005).
6
See Brian C. Watts, V. Health Law: The Genetic Testing Privacy Act,
2003 UTAH L. REV. 807, 809 (2003).
7
H.R. 1227, 109th Cong. (2005).
4
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legislation. The Note concludes that federal legislation is
warranted, and that GINA provides a viable solution to the
problems of genetic discrimination.
I. BACKGROUND ON GENETIC INFORMATION; CURRENT
DEVELOPMENTS
Genetic information is contained in the DNA of every living
organism.8 Each molecule of DNA, or deoxyribonucleic acid, is
composed of two paired strands of nucleotides which are twisted
together to form a double helical structure.9 Nucleotides contain
one of four nitrogenous bases.10 Each nucleotide base pair is
connected to the next, forming the chain of pairs that make up
DNA.11 In human cells, DNA is organized into twenty-three
matched pairs of chromosomes.12 The DNA codes for the
production of specific proteins in the cell, thereby directing the
cell’s function.13 The vast majority of DNA found in human
cells is uniform among all human beings.14 However, variations
in the ordering of base pairs in an individual’s DNA account for
differences in the population.15 During replication of the cell’s
DNA, mistakes in the arrangement of the nucleotide bases can
occur, resulting in mutations of the genetic material.16
The recently completed Human Genome Project17 has opened

8

DNA, Funk & Wagnalls New Encyclopedia (2005).
Nicholas Wade, Watson and Crick, Both Aligned and Apart,
Reinvented Biology, N.Y. TIMES, Feb. 25, 2003, at F3.
10
DNA, supra note 8.
11
Id.
12
Id.
13
Id.
14
Jonathan Weems, A Proposal for a Federal Genetic Privacy Act, 24 J.
LEGAL MED. 109, 111 (2003).
15
Genetics, Funk & Wagnalls New Encyclopedia (2005).
16
Id.
17
The Project was completed in 2003, and provides a blueprint of all of
the genetic data contained in the human genome. All About the Human
Genome Project, http://www.genome.gov/10001772 (last visited Sep. 26,
2006).
9
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up new avenues of discovery for scientists and physicians
seeking to understand the underlying genetic bases of various
diseases and pathological states.18 It is believed that almost every
human illness has a genetic component.19 By comparing the
known genetic sequence garnered from the Human Genome
Project with the genetic sequence of an affected population,
scientists can identify the segment of the genome that is
implicated in a particular condition.20 The capability for such
identifications has led to the development of genetic testing. The
detection of the presence or absence of particular DNA
fragments in an individual’s genome is invaluable for accurate
diagnosis of disease and for determination of the propensity of a
patient to develop various conditions.21 As scientists continue to
unravel the genetic code, the significance of genetic testing will
surely increase.22
There are currently over 900 different genetic tests
18

See Stephanie L. Anderson, Genetic Privacy: A Challenge to MedicoLegal Norms, Graeme Laurie, 25 J. LEGAL MED. 119, 119 (2004) (book
review).
19
Abigail L. Rose, Nikki Peters, Judy A. Shea & Katrina Armstrong,
Attitudes and Misconceptions about Predictive Genetic Testing for Cancer
Risk, 8 COMMUNITY GENETICS 145, 148 (2005). This notion may be what
prompted James Watson, the co-discoverer of the structure of DNA, to
declare, “In large measure, our fate is in our genes.” Leon Jaroff, The Gene
Hunt Scientists, TIME, March 20, 1989, at 67.
20
Jennifer Chorpening, Genetic Disability: A Modest Proposal To
Modify the ADA to Protect Against Some Forms of Genetic Discrimination,
82 N.C.L. REV. 1441, 1442 (2004).
21
See, e.g., Weems, supra note 14. An individual’s DNA can be easily
examined once a tissue sample is obtained. A variety of procedures have been
developed to accomplish this. Id.; See also Jordan K. Garrison, Note, Courts
Face the Exciting and the Inevitable: DNA in Civil Trials, 23 REV. LITIG.
435, 438 (2004) (quoting French Nobel laureate Jean Dausset on the value of
genetic testing, “medicine was, in its history, first of all curative, then
preventative and finally predictive, whereas today the order is reversed:
initially predictive, then preventative and finally, only in desperation,
curative.”).
22
See, e.g., Weems, supra note 14; Anita Silvers & Michael Ashley
Stein, Human Rights and Genetic Discrimination: Protecting Genomics’
Promise for Public Health, 31 J. L. MED. & ETHICS 377, 377 (2003).
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available.23 Some of these tests are diagnostic, while others
identify susceptibility to specific diseases.24 It is critical to
understand the significance of these tests, and perhaps more
importantly, to understand their limitations. A genetic test “can
tell if a mutation is present, but that finding does not guarantee
that disease will develop.”25 For example, a genetic test
revealing that a woman’s DNA contains the BRCA1 gene
indicates that she has an 80% chance of developing breast
cancer.26 However, it is entirely possible that she will never
develop the disease.27 Equally important, a negative result of a
BRCA1 test does not mean that a woman is risk-free.28 She still
sustains many other risk factors (both genetic and
environmental).29 Although the result of this particular genetic
test does not conclusively predict whether a woman will or will
not develop breast cancer, the test remains useful because it
allows a high risk individual to take preventative steps to reduce
the probability of occurrence of disease.30
More controversial are tests which screen for diseases for
which there are no known ways of avoiding or limiting the
severity of the disease.31 In addition, most pathophysiological
conditions are complex, many requiring an interaction between
23

See Human Genome Project Information: Gene Testing,
http://www.ornl.gov/sci/techresources/Human_Genome/medicine/genetest.sht
ml (last visited Oct. 28, 2005).
24
Id.
25
Lydia Schindler, Donna Kerrigan, Jeanne Kellen & Brian Hollen,
National Cancer Institute, Understanding Gene Testing (2005),
http://nci.nih.gov/cancertopics/understandingcancer/genetesting/Slide29.
26
Id.
27
Id.
28
Id.
29
Only five to ten percent of all breast cancer incidence is attributed to a
genetic factor. See National Cancer Institute, Genetic Testing for BRCA1 and
BRCA2: It’s Your Choice (2002), http://www.cancer.gov/cancertopics
/factsheet/Risk/BRCA.
30
See, e.g., Mendel E. Singer & Randall D. Cebul, BRCA1: To Test or
Not to Test, That is the Question, 7 HEALTH MATRIX 163, 164 (1997).
31
See Schindler et al., supra note 25, at http://nci.nih.gov/cancertopics/
understandingcancer/genetesting/Slide32.
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two or more defective genes.32 For many conditions, such as
heart disease and diabetes, genetic susceptibility must be
understood within the context of other important factors such as
environmental influences, nutrition, and lifestyle.33
II. OCCURRENCE OF GENETIC DISCRIMINATION
Along with enhanced understanding and treatment of human
disease, the completion of the Human Genome Project along
with the growing availability of genetic testing has resulted in
increased concern about genetic discrimination.34 Genetic
discrimination has been defined in various ways. In one widely
cited study of genetic discrimination, the term was defined as
“the denial of rights, privileges or opportunities on the basis of
information obtained from genetically-based diagnostic and
prognostic tests.”35 Others extend the term to include “such
denials on the basis of assumptions stemming from family
histories . . . as well as from ethnic group identification.”36
32

GRAEME LAURIE, GENETIC PRIVACY: A CHALLENGE TO MEDICOLEGAL NORMS 94 (2002). Diseases which are caused by a single defective
gene, such as cystic fibrosis, muscular dystrophy, and retinitis pigmentosa are
more predictable. Jordan K. Garrison, Note, Courts Face the Exciting and
the Inevitable: DNA in Civil Trials, 23 REV. LITIG. 435, 438-439 (2004).
33
Jacquelyn Ann K. Kegley, Confused Legal and Medical Policy: The
Misconceptions of Genetic Screening, 19 MED. & L. 197, 200 (2000). This
explains the statement of Dr. Craig Venter at an event celebrating the
completion of the Human Genome Project, “Our physiology is based on
complex and seemingly infinite interactions amongst all our genes and the
environment, just as our civilization is based on the interactions amongst all
of us.” Remarks by President Bill Clinton and British Prime Minister Tony
Blair at Announcement on Human Genome Project, Fed. News Serv. (2000).
34
Following the announcement in 2000 that a rough map of the human
genome had been created, this concern was expressed by Dr. Francis Collins,
Dr. Craig Venter, and President Bill Clinton. See Remarks by President Bill
Clinton and British Prime Minister Tony Blair at Announcement on Human
Genome Project, Fed. News Serv. (2000).
35
Lawrence O. Gostin, Genetic Discrimination: The Use of Genetically
Based Diagnostic and Prognostic Tests by Employers and Insurers, 17 AM. J.
L. & MED. 109 (1991).
36
See Janet L. Dolgin, Personhood, Discrimination, and the New
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Concerns about the misuse of genetic information, whether the
information is gleaned from a genetic test or from an
individual’s family history, are valid. While the discrimination
may occur in a variety of arenas, the two particular areas of
concern which have emerged are the employment setting and
health insurance.37
Genetic testing prior to finalizing employment decisions has
become increasingly commonplace.38 Information obtained in a
genetic screen can be used to predict the likelihood of certain
risks associated with the potential employee, such as the need
for increased health care benefits and workers’ compensation
claims.39 It might also be used to predict cost-related factors
such as potential absenteeism or employee turnover.40 Employers
may request genetic information prior to hiring an employee in
order to ascertain various safety risks linked to the nature of the
employment.41 Several recent surveys indicated that workplace
genetic discrimination does occur with some frequency.42
Genetics, 66 BROOK. L. REV. 755, 771 (2001).
37
Deborah Hellman, What Makes Genetic Discrimination Exceptional?,
29 AM. J. L. & MED. 77, 83 (2003). Other areas in which genetic
discrimination may occur include child custody disputes, adoption prospects,
and abortion. Id.
38
Brian M. Holt, Genetically Defective: The Judicial Interpretation of
the Americans with Disabilities Act Fails to Protect Against Genetic
Discrimination in the Workplace, 35 J. MARSHALL L. REV. 457, 460 (2002);
See Silvers & Stein, supra note 22, at n.23.
39
Holt, supra note 38, at 460-61.
40
See Jeremy A. Colby, An Analysis of Genetic Discrimination
Legislation Proposed by the 105th Congress, 24 AM. J. L. & MED. 443, 462
(1998).
41
Chorpening, supra note 20, at 1445. For example, a workplace
chemical, such as benzene, has been shown to be more carcinogenic in
individuals with a particular genetic susceptibility. Screening potential
employees for this sensitivity could result in a safer work environment. See
id. at n.32.
42
A 1996 survey conducted by the Genetic Alliance found 13% of
respondents had experienced various forms of employment discrimination
based on their genetic makeup. Watts, supra note 6, at 809. In 1989, a
Congressional study found at least 12 Fortune 500 companies that used
genetic monitoring to screen their employees. Robert F. Rich & Julian
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Further, these issues have reached the courtroom as well via
employees who claimed they were discriminated against on the
basis of their genetic information.43
In many instances, an employee’s genetic predisposition to
develop a disease will have no impact on job performance.44
Indeed, in the employment setting, this information is typically
not discovered until after an offer of employment has been
extended, indicating that the employer has already made a
factual determination that the applicant is qualified to perform
the job.45 Since genetic tests indicate only a propensity to
develop a disease or condition, the employee may never be
affected by it at all. Therefore, it is important to safeguard job
applicants from genetic discrimination.
Similarly, insurance companies have a cost incentive to
discriminate based on information obtained through genetic tests,
as this information can be an indicator of probable risk.46
Indeed, pricing of insurance has always reflected risk, and in
this way, people who are at lower risk are able to avoid the cost

Ziegler, Genetic Discrimination in Health Insurance—Comprehensive Legal
Solutions for a (Not so) Special Problem?, 2 IND. HEALTH L. REV. 5, 5
(2005). For a detailed discussion of the current state of genetic testing in the
workplace environment, see Paul Steven Miller, Is There a Pink Slip in My
Genes? Genetic Discrimination in the Workplace, 3 J. HEALTH CARE L. &
POL’Y 225, 232-37 (2000).
43
E.g. Norman-Bloodsaw v. Lawrence Berkeley Laboratory, 135 F.3d
1260 (9th Cir. 1998) (in which an employer required genetic testing of
particular groups of individuals prior to employment); in another case, the
E.E.O.C. brought suit against Burlington Northern Santa Fe Railroad for
secretly testing its employees for a rare genetic condition. The case was
settled for 2.2 million dollars. See National Human Genome Institute, Cases
of Genetic Discrimination (2006), http://www.genome.gov/12513976.
44
See Nancy Lee Jones & Alison M. Smith, Genetic Information: Legal
Issues Relating to Discrimination and Privacy, CRS REP. FOR CONG. NO.
RL30006, at 4-5 (2005).
45
See Nicole Silvestri, Echazabal and the Threat to Self-Defense: The
Most Recent Call for a Consistent, Interstate Genetic Nondiscrimination
Policy, 7 U. PA. J. LAB. & EMP. L. 409, 421 (2005).
46
David F. Partlett, Misuse of Genetic Information: The Common Law
and Professionals’ Liability, 42 WASHBURN L.J. 489, 503 (2003).
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of subsidizing the higher risk population.47
The Genetic Alliance, a national advocacy group for
individuals with genetic diseases, recently reported that it
receives an average of two complaints per week about genetic
discrimination.48 However, the frequency of such complaints has
not translated into frequent lawsuits by the victims. The
discrepancy may be due not only to the fact that genetic
discrimination can be difficult to prove, but also to the lack of a
comprehensive genetic discrimination statute under which to sue.
The current mélange of state and federal laws addressing genetic
discrimination is, for the most part, too weak to support
potential claims.49 Some victims have indicated a hesitancy to
sue over genetic discrimination for fear of bureaucratic barriers
as well as further negative treatment resulting from publicity of
their genetic data.50
External pressures exist for both insurers and employers to
avoid discriminating based on genetic factors.51 Some insurers
may be cognizant of the limitations of genetic tests as predictors
of disease, while others may want to avoid the possibility of
potentially damaging discrimination lawsuits.52 Employers may
also seek to avoid such suits.53 However, occurrences of genetic
discrimination in both employment and insurance are expected to
increase over time as genetic testing becomes more
comprehensive and methods even more sophisticated.54

47

Id. at 503-04.
See Steve Lohr, I.B.M. to Put Genetic Data of Workers Off Limits,
N.Y. TIMES, Oct. 10, 2005, at C1.
49
See discussion of state and federal legislation infra Part IV.B-C; See
also Tresa Baldas, Legal Tension Grows over Genetic Tests; Privacy,
Potential Discrimination are Major Concerns, NAT’L L.J., Oct. 31, 2005, at
P1.
50
See Peter Aldhous, Victims of Genetic Discrimination Speak Up, NEW
SCIENTIST, Nov. 5, 2005, at 7.
51
Partlett, supra note 46, at 518-19.
52
Id.
53
Id. at 519.
54
See Ronald M. Green & A. Matthew Thomas, DNA: Five
Distinguishing Features for Policy Analysis, 11 HARV. J.L. & TECH. 571
48
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Moreover, refinement of gene testing methodology will lead to
reduced testing costs, further broadening the appeal of such tests
to employers and insurers.55
III. PURPOSE & SCOPE OF GINA—THE GENETIC INFORMATION
NONDISCRIMINATION ACT
The Genetic Information Nondiscrimination Act56 (GINA)
was unanimously approved in the U.S. Senate on February 17,
2005.57 An identical companion bill was introduced in the House
of Representatives in March 2005.58 In addition to prohibiting
genetic discrimination by employers and insurers,59 GINA
contains provisions safeguarding the privacy of genetic
information.60 Despite the unanimous Senate approval as well as
the support of President Bush61 and numerous interest groups
such as the American Medical Association and the ACLU,62 the
bill remains pending in the House.63
GINA was introduced as a targeted effort to combat genetic

(1998); See also Rich & Ziegler, supra note 42, at 14.
55
Rich & Ziegler, supra note 42, at 5.
56
Genetic Information Nondiscrimination Act, S. 306, 109th Cong.
(2005) (identical to H.R. 1227, 109th Cong.).
57
See Bill Summary & Status for the 109th Congress, S. 306,
http://www.thomas.gov/cgi-bin/bdquery/z?d109:SN00306:@@@R
(last
visited October 11, 2006).
58
Genetic Information Nondiscrimination Act, H.R. 1227, 109th Cong.
(2005).
59
See id.
60
Id.
61
Helen Dewar, Senate Backs Safeguards for Genetic Data; Employers,
Insurers Targeted, THE WASH. POST, Oct. 15, 2003, at A10; Statement of
Administration Policy, S. 306 – Genetic Information Nondiscrimination Act of
2005, reprinted in 151 CONG. REC. S. 1481 (daily ed. Feb. 16, 2005).
62
Rich & Ziegler, supra note 42, at 5.
63
The legislation remains pending at the time of this publication. See
Bill Summary & Status for the 109th Congress, H.R. 1227,
http://thomas.loc.gov/cgi-bin/bdquery/z?d109:h.r.01227
(last
visited
September 8, 2006). There are currently 232 cosponsors in the House. Id.
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discrimination.64 Its supporters found existing federal and state
laws inadequate to provide the necessary protections to
individuals seeking genetic tests.65 GINA is designed to combat
discrimination which is based solely on genetic information, that
is, information obtained through a genetic test or indicated by
the occurrence of a defect or disease in an individual’s family.66
Further, the existence of a request by an individual or an
individual’s family member for genetic testing is also protected
genetic information.67 The Act restricts both insurers and
employers from using genetic information to discriminate in
several ways.
Title I of GINA amends three existing federal laws in order
to expressly prohibit insurers from restricting or denying
enrollment in any health plan based on an individual’s genetic
information.68 It also prevents insurers from setting an
individual’s premiums based on such information, or using such
information for any underwriting purposes.69 Insurers are also
barred from requiring an individual to undergo a genetic test as
a condition of insurability or of continuing coverage.70 GINA
provides broad protection to group health plan members by
forbidding the adjustment of premiums for an entire group based
on the genetic information of one or more individuals within the
group.71
Under Title II, employers, employment agencies, and labor
organizations may not make hiring or membership decisions or
otherwise discriminate against an individual based on that
64

See Genetic Information Nondiscrimination Act, H.R. 1227, 109th
Cong. § 2 (2005).
65
Id.; See also discussion infra Part IV.B-C.
66
H.R. 1227, 109th Cong. § 201 (2005).
67
Id.
68
H.R. 1227, 109th Cong. §§ 101–103 (2005). The following federal
laws are amended by GINA: The Employee Retirement Income Security Act
of 1974, The Public Health Service Act, and Title XVIII of the Social
Security Act. Id.
69
H.R. 1227, 109th Cong. §§ 101(b), 104(b)(2) (2005).
70
H.R. 1227, 109th Cong. § 101(b) (2005).
71
Id. at § 101(a)(2)-(3).
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person’s genetic information.72 For the most part, these entities
may not “request, require, or purchase genetic information”
about their employees, although there are five categories of
exception.73 If an employer obtains genetic information through
an exception, the employer may only disclose the information to
specific parties as mandated by the particular exception.74
Finally, Title II provides remedies to various groups of
employees who have been the victim of an employment practice
contrary to the provisions of the Act.75 The remedies include
damages as well as costs and fees.76
In accordance with the still evolving science of genetic
testing and the uncertainties inherent in legislating a matter not
yet fully developed, the drafters of GINA included a provision
in the Act which provides for a review of the legislation six
years after its enactment.77 Specifically, the bill provides for the
establishment of a Genetic Nondiscrimination Study Commission
six years after GINA is passed, to study the impact of the
legislation, to report on the current status of genetic science, and
to make recommendations to Congress accordingly.78
The Genetic Information Nondiscrimination Act of 2005
differs from previously proposed genetic nondiscrimination
72

Id. at §§ 202(a), 203(a), 204(a) (2005).
Id. at §§ 202(b), 203(b), 204(b) (2005). The exceptions include, inter
alia, where health or genetic services are offered by the employer as part of
a wellness program, where the employee provides written authorization,
where necessary for an employer to comply with the provisions of the Family
and Medical Leave Act of 1993 (29 U.S.C. 2613), and where the genetic
information is to be used for monitoring of the effects of toxic substances in
compliance with a Federal genetic monitoring regulation such as the
Occupational Safety and Health Act of 1977 (30 U.S.C. 801). Id.
74
H.R. 1227, 109th Cong. § 206(b) (2005). For example, if the
information was collected in order for the employer to comply with the
provisions of the Family and Medical Leave Act, the information may be
disclosed in connection with the employer’s compliance with the Act’s
requirements. Id.
75
H.R. 1227, 109th Cong. § 207 (2005).
76
Id.
77
Id. at § 208(b).
78
Id.
73
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legislation in several ways. Its definition of “genetic
information” is more narrow, so that it excludes information
about a genetic disease that is evident through a manifested
disease or condition, as well as information obtained through a
genetic test when the information is related to a manifested
disease or condition.79 Other distinctions include the requirement
that individuals with discrimination claims seek redress with the
Equal Employment Opportunity Commission (EEOC) before
filing claims for damages in court, and the adoption of standards
for the amount of punitive damage awards that can be
obtained.80 With these modifications, the current bill may be
able to address some of the concerns that have prevented
legislation from moving forward in previous sessions of
Congress.
IV. WHY FEDERAL GENETIC NONDISCRIMINATION LEGISLATION
MUST BE PASSED
Although GINA has generally achieved widespread backing
and acceptance,81 some key groups remain unconvinced of the
need for federal genetic nondiscrimination legislation.82 The
bill’s opponents, most notably the U.S. Chamber of Commerce,
cite several basic reasons for their reluctance to support the bill.
As a threshold matter, they do not find genetic discrimination
different from other types of health status discrimination.83

79

Id. at § 201 (2005).
H.R. 1227, 109th Cong. § 207 (2005).
81
See discussion supra Part III. In the House of Representatives, H.R.
1227 has 232 cosponsors. See Bill Summary & Status for the 109th
Congress,
H.R.
1227,
http://thomas.loc.gov/cgi-bin/bdquery/z?d109:
h.r.01227 (last visited September 8, 2006).
82
The two major groups opposing the legislation are the U.S. Chamber
of Commerce and the National Association of Manufacturers. Frequently
Asked Questions: Genetic Information Nondiscrimination Act (H.R. 1227),
http://geneticfairness.org/faq.html (last visited November 25, 2005).
83
See Hearing Before the H. Subcomm. on Employer-Employee
Relations of the H. Comm. on Education and the Workforce, 108th Congress
(2004) (statement of Lawrence Z. Lorber, Partner, Proskauer Rose LLP, on
80
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Further, they maintain that recently enacted state genetic
discrimination laws, as well as existing federal antidiscrimination
laws,
provide
sufficient
protections
against
genetic
84
discrimination. Some believe that genetic discrimination rarely
occurs, and that non-legislative means can be employed to
vanquish such fears.85 This section addresses each of these
claims and concludes that the need for a statute such as GINA is
significant.
A. Genetic Discrimination is Different from Other Types of
Discrimination
1. Genetic Information is Different than
Ordinary Medical Information
Commentators caution against singling out parts of the
population for inclusion in an antidiscrimination statute because
of the likelihood that every person possesses genetic defects to
some extent.86 Arguably, it is difficult to differentiate between
discrimination based on genetic information and discrimination
based on other medical or circumstantial information,
particularly for multifactorial diseases.87 Genetic exceptionalism,
the idea that a person who has a genetic predisposition to a
disease should receive extra protection, but a person with an
environmentally based disease should not, has been cited as an
argument against legislation such as GINA.88 One concern of
those who warn against genetic exceptionalism is that legislating
behalf of the United States Chamber of Commerce).
84
See id.
85
See id.; Mark A. Hall & Stephen S. Rich, Genetic Privacy Laws and
Patients’ Fear of Discrimination by Health Insurers: The View from Genetic
Counselors, 28 J. L. MED. & ETHICS 245, 254-55 (2000).
86
See Chorpening, supra note 20, at 1472; Susan. M. Wolf, Beyond
Genetic Discrimination: Toward the Broader Harm of Geneticism, 23 (4) J.L.
MED. & ETHICS 345 (1995).
87
See Silvers & Stein, supra note 22, at 382.
88
See Chorpening, supra note 20, at 1472.
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against genetic discrimination, in and of itself may effectively
label those who are discriminated against as inferior to the
purportedly “normal” population.89
Despite these arguments, genetic discrimination is separate
and distinct from other sorts of discrimination. While it has been
suggested that genetic information should not be singled out for
protection beyond other health related information,90 genetic
information differs significantly. More than just another variety
of medical examination, genetic testing “offer[s] tremendous
quantitative differences.”91 Part of the difference is that genetic
tests have the potential to reveal much more about a patient than
any single medical test could. Testing for many genetic factors
in a single profile is expected to become more cost effective,
encouraging or even mandating testing for many factors even
when information is only sought regarding one gene.92 A single
genetic profile could include thousands of genetic risk factors for
ailments ranging from diseases to psychosocial ailments, such as
drug addiction or impulsiveness.93 In this way, genetic testing
carries long range prediction capabilities apart from those of
more traditional medical tests.94
Another distinguishing factor between genetic information
and other medical information is the way in which such data
might be used by insurers for underwriting purposes. Arguably,
GINA’s restrictions on the use of genetic information adversely
89

See Wolf, supra note 86. For a critique of Professor Wolf’s view of
genetic exceptionalism, arguing that Wolf fails to explain why this sort of
inequality is morally problematic, see Deborah Hellman, What Makes Genetic
Discrimination Exceptional?, 29 AM. J. L. & MED. 77, 90-92 (2003).
90
See, e.g., Chorpening, supra note 20, at 1441; Garrison, supra note
21, at 446 (discussing the finding of the Task Force on Genetic Information
and Insurance of the NIH-DOE Joint Working Group on the Ethical, Legal,
and Social Implications of the Human Genome Project, denying genetic
exceptionalism).
91
Weems, supra note 14, at 111-12.
92
See Michele Schoonmaker & Erin D. Williams, Genetic Testing:
Scientific Background and Nondiscrimination Legislation, CRS REP. FOR
CONG. NO. RL32478, at 17 (2005).
93
Weems, supra note 14, at 111.
94
See Schoonmaker & Williams, supra note 92, at 16.
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affect the underwriting process, resulting in poorly leveraged
premiums among individuals with varying degrees of risk.95
However, due to the inconclusive nature of most test results
(given that the majority of genetic diseases are multifactorial), it
is unclear that such calculations would be reasonable.
It is important to note that GINA does not address the use of
medical information derived from methods other than genetic
testing. Insurers may continue to use disease diagnosis
(including diagnosis of a genetic disease) or other indicators of
risk for underwriting purposes. The Act thus recognizes that it is
the discriminatory use of inconclusive genetic information which
requires protection, rather than a more appropriate use of
existing disease for underwriting purposes. This is one of the
ways in which H.R.1227 differs from previous incarnations of
the bill, as its definition of “genetic information” excludes
information obtained through a genetic test that is related to a
clinically present disease.96
2. Widespread Fear of Genetic Discrimination
Prevents People from Getting Tested
Perhaps the largest distinction between genetic and other
forms of discrimination lies in the public perception of genetic
testing.97 Despite the relatively low incidence of genetic
discrimination, it is clear that many people forego possibly
beneficial genetic testing for fear that discrimination may
occur.98 For similar reasons, many decline participation in
potentially valuable research trials.99 These fears exist in the
absence of factual cases indicating that genetic discrimination

95

Rich & Ziegler, supra note 42, at 40.
See H.R. 1227, 109th Cong. § 201 (2005).
97
See Anderson, supra note 18, at 124.
98
Hall & Rich, supra note 85, at 245; See also Watts, supra note 6, at
809; Silvers & Stein, supra note 22, at 377.
99
See Letter from The Secretary’s Advisory Committee on Genetic
Testing to Secretary Tommy Thompson 1 (2001), http://www4.od.nih.gov/
oba/sacgt/ltr_to_secDHHS5-3-01.pdf.
96
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actually occurs to any significant extent.100 Thus, even in the
absence of the clear distinctions between genetic discrimination
and other health-related discrimination described above, a
practical need to address the fears arises.
It is imperative to understand the bases for this fear in any
effort to combat their existence. For some, the fear may be
explained by examining the historical perceptions of those who
were thought to be genetically inferior.101 However, the majority
of the fear may be attributed to scientific illiteracy in the general
public,102 misconceptions among various groups of people,103
and the existence of other sorts of privacy invasions which leave
individuals apprehensive about how their genetic privacy will be
protected.
There have been some historical incidents of discrimination
on a genetic basis. In the early twentieth century the eugenics
movement represented an attempt to weed out inferior people
from the evolutionary chain.104 The movement was spurred by
Charles Darwin’s work on evolution, and eugenics was thought
to be the responsible way for society to promote the survival of
the most suitable candidates to perpetuate the human species.105
During the same time period, eugenics was also espoused by the
Supreme Court, when it upheld a Virginia statute permitting the
forced sterilization of a “feeble minded” woman, whose mother
and child were also “feeble minded.”106 Writing for the

100

Hall & Rich, supra note 85, at 245.
See, e.g., Rose et al., supra note 19, at 149.
102
See Cornelia Dean, Scientific Savvy? In U.S., Not Much, N.Y.
TIMES, Aug. 30, 2005, at F3.
103
Hall & Rich, supra note 85, at 245 (blaming misconceptions for
reluctance to undergo genetic testing); See also Kegley, supra note 33, at 198
(discussing various misconceptions about genetic testing among individuals);
Rose et al., supra note 19, at 148; Garrison, supra note 21, at 436
(indicating that even courts are not immune from misconceptions regarding
genetic information).
104
Eugenics, Funk & Wagnalls New Encyclopedia (2004).
105
Id.
106
Buck v. Bell, 274 U.S. 200, 205 (1927). Many states enacted
sterilization laws targeting genetically defective populations, following early
101
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majority, Justice Holmes determined that it was prudent to
prevent the birth of children likely to drain the resources of
society, reasoning that, “It is better for all the world, if instead
of waiting to execute degenerate offspring for crime, or to let
them starve for their imbecility, society can prevent those who
are manifestly unfit from continuing their kind.”107 The
popularity of eugenics waned quickly during the Nazi era, when
Hitler utilized eugenic philosophy to justify his schematic
attempt to rid the world of allegedly inferior people, such as
Jews and homosexuals.108 Although eugenics as a discipline is
not currently favored by the scientific community, and no longer
appeals to the general public, some fear lingers concerning a
revival of this sort of discriminatory practice.109
A more recent instance of genetic discrimination occurred in
the 1970s with the discovery of a gene associated with sickle
cell anemia.110 The gene is found primarily in African-American
populations.111 Scientists found that carriers of the gene might be
more susceptible to particular workplace toxins.112 As a result,
many African Americans reported experiencing discrimination in

developments in genetic science at the beginning of the twentieth century.
The targeted defects included mental illness, blindness, and hearing loss,
among others. GINA is an effort to prevent such discriminatory practices in
the wake of the current major expansion of the capabilities of genetic science.
See Genetic Information Nondiscrimination Act, H.R. 1227, 109th Cong. § 2
(2005).
107
Id. at 207.
108
See Weems, supra note 14, at 113.
109
Id. See also Rose, supra note 19, at 148 (discussing a 2005 study in
which some participants thought that the purpose of genetic testing was “to
create a superior race”); Mark A. Rothstein, Preventing the Discovery of
Plaintiff Genetic Profiles by Defendants Seeking to Limit Damages in
Personal Injury Litigation, 71 IND. L. J. 877, 894 (1996) (discussing the
possibility that genetic information may be used in the future for eugenic
purposes).
110
See, e.g., Marisa Anne Pagnattaro, Genetic Discrimination and the
Workplace: Employee’s Right to Privacy v. Employer’s Need to Know, 39
AM. BUS. L. J. 139, 146-47 (2001).
111
Id.
112
Id.
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hiring and firing decisions.113 Some wrongly assumed that
African Americans were more prone to genetic disease than
other populations.114 It is possible that the fears underlying the
reluctance of people to undergo genetic testing today may be
understood in relation to this relatively recent occurrence of
resultant discrimination.
In addition to these historical incidents of genetic
discrimination, the fear of genetic discrimination among the
general public may be attributed in part to scientific illiteracy.
One genetic counselor at a cancer clinic explained that patients
who come in to clinics are very much aware, and afraid of
genetic discrimination.115 Yet for the most part, they “don’t
know anything about genetics,” nor can they identify what a
geneticist or a genetics counselor is.116 Jon Miller, who studies
the current level of scientific understanding among Americans,
found in a recent survey that less than one-third of adults in this
country could articulate what DNA is.117 In a recent interview,
Miller said that less than 25% of Americans “are scientifically
savvy and alert,” while the remainder of the population
“[doesn’t] have a clue.”118 Perhaps more worrisome is the alarm
expressed by some that scientific literacy among biomedical
policy leaders may be low as well.119
In a 1995 U.S. study, only about half of respondents

113

Id.
This incorrect assumption has been made regarding other groups,
particularly Ashkenazi Jews. See Janet L. Dolgin, Personhood,
Discrimination, and the New Genetics, 66 BROOK. L. REV. 755, 790 (2001).
In fact, everyone shares a similar risk of genetic mutations, as indicated by
the statement of Dr. Francis Collins, “There is no evidence that the burden
of genetic flaws is greater for one population than another.” Id. at 791.
115
Hall & Rich, supra note 85, at 246.
116
Id.
117
Dean, supra note 102. Miller is the director of the Center for
Biomedical Communications at Northwestern University Medical School, and
is widely regarded as an authority on scientific literacy. Id.
118
Id.
119
JON D. MILLER & LINDA G. KIMMEL, BIOMEDICAL COMMUNICATIONS
302 (2001); See also Rich & Ziegler, supra note 42, at 8.
114
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understood that if a doctor tells a couple that a genetic test
indicates that they have a one-in-four chance of having a child
with a genetic disease, each child that the couple has would
sustain the same risk of having the disease.120 Considering that
about half of the populations in industrialized societies are active
in deciding issues of public policy,121 and far less than half are
considered “scientifically savvy,”122 it becomes clear that
decision-making on many levels may be affected by fears that
are not factually based.
Given that so many in the general population lack basic
scientific understanding, it is not surprising that misconceptions
about genetic testing abound. One common misconception is the
belief that genes alone determine disease states.123 With the
exception of a few rare instances, most genes should actually be
regarded as factors in a complex interaction of environmental
elements which could potentially, but not determinedly, combine
to bring about clinical disease.124 In some cases, fear of genetic
discrimination is tied to the belief that a defective gene is
somehow indicative of a defective identity.125 Under that
perception, people are afraid that if a mutation or defect is
discovered in their genetic makeup, they will be seen as inferior

120

JON D. MILLER, RAFAEL PARDO, & FUJIO NIWA, PUBLIC
PERCEPTIONS OF SCIENCE AND TECHNOLOGY 54(1997). Respondents were
asked to choose between four possible interpretations of the meaning of “onein-four chances.” The choices were:
[a] if they have only three children, none will have the illness
[b] if their first child has the illness, the next three will not
[c] each of the couple’s children has the same risk of suffering from
the illness
[d] if their first three children are healthy, the fourth will have the
illness.
Id. 54% of respondents selected choice c. Id.
121
Id. at 7.
122
Dean, supra note 102.
123
See Rose et al., supra note 19, at 148.
124
Kegley, supra note 33, at 200.
125
Id. at 199.
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to others, and discrimination will result.126 These sorts of
pervasive misconceptions among the general population are often
determinative of whether someone will choose a genetic test.127
Indeed, even when patients are informed that there have not
been widespread reports of genetic discrimination, many still
choose to forego testing.128
Misconceptions concerning genetic information occur among
insurers as well. For example, some genetics counselors warn
patients who are considering genetic tests about the possibility of
resultant insurance discrimination because they believe that
insurers are likely to misconstrue the results of tests.129 An
insurer may misinterpret a carrier as an affected person or a
person at risk for the disease, or may not appreciate that
although a genetic predisposition is present, symptoms may not
manifest themselves for years.130 Thus, it is thought that there is
a lack of scientifically sound judgment on the insurer level as
well.131 As a result, even when an individual understands the
limits and capabilities of genetic testing, that individual may still
resist testing for fear that other parties may misconstrue the
meaning of the test results.
Another contributing factor to the fear of genetic
discrimination is the vulnerability that people may feel as a
result of other unrelated privacy intrusions. For example,
identity theft is a common occurrence that receives widespread

126

Id. The fears include fears of societal discrimination, fueled by
general societal misunderstanding of genetic defects. See Ronald M. Green &
A. Matthew Thomas, DNA: Five Distinguishing Features for Policy Analysis,
11 HARV. J.L. & TECH. 571, 584-85 (1998). This is particularly the case in
the wake of recent claims by scientists of links between genetic mutations and
behavioral traits. See Dolgin, supra note 36, at 767-68.
127
Hall & Rich, supra note 85, at 245; see also Rose et al., supra note
19, at 145.
128
Hall & Rich, supra note 85, at 245.
129
Id. at 247.
130
Id. For example, insurers “may not appreciate the fact that mild
forms of muscular dystrophy exist in which symptoms do not occur for many
years.” Id.
131
Id; See also MILLER & KIMMEL, supra note 119, at 302.
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media attention.132 This creates an increased awareness among
people as to the potential effects of exposure of personal
information to others. Widespread reports concerning the
dissemination and abuse of confidential information have led
many to blame the Internet and other technologies for an overall
diminution of privacy interests.133 The insecurity inherent in
surrendering personal details such as social security numbers,
addresses, and medical information, might carry over to genetic
information as well.134 In reality, as a result of the illiteracy and
the misconceptions described above, individuals may be more
fearful about loss of genetic privacy than any other closely held
privacy interests.
In addition, the popular media repeatedly contains, with little
basis, warnings about genetic discrimination.135 This feeds into
the public’s general fears about invasions of privacy. Some have
attributed public misconceptions about genetic testing to mass
media reports which are often “misleading[,] and may confuse
more than clarify.”136 Much of the information about genetic
testing is learned outside the health care or research setting,
including the learning done by health care professionals,
insurers, and individual patients.137

132

See, e.g., JOHNNY R. MAY, JOHNNY MAY’S GUIDE TO PREVENTING
IDENTITY THEFT 1-2 (2004).
133
See, e.g., Alison Gardy, A Lost Baby, and the Pain of Endless
Reminders in the Mail, N.Y. TIMES Sep. 20, 2005, at F5 (describing a case
of harassment by baby product companies following woman’s failed
pregnancy).
134
See LAURIE, supra note 32, at 108.
135
Hall & Rich, supra note 85, at 247; see also Neil A. Holtzman,
Barbara A. Bernhardt, Eliza Mountcastle-Shah, Joann E. Rodgers, Ellen
Tambor, & Gail Geller, The Quality of Media Reports on Discoveries Related
to Human Genetic Diseases, 8 COMMUNITY GENETICS 133, 133-40 (2005)
(Americans learn about genetic discoveries from television reports, which are
often incomplete).
136
Rose et al., supra note 19, at 149.
137
See id.
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B. Individual State Laws Are Insufficient
There are currently thirty-three states with statutes
specifically targeting genetic discrimination in employment.
Additionally, every state except Mississippi, North Dakota, and
Pennsylvania has statutes aimed at preventing genetic
discrimination in health insurance.138 However, the individual
provisions in these statutes offer widely varying degrees of
protection.139 In particular, the threshold determination of what
constitutes genetic information differs from state to state. While
some states protect genetic information derived from individual
or family medical histories as well as the results of genetic tests,
others limit the protection to genetic test results alone.140
Although state protection may seem sufficient on the surface,
the portability of information, mobility of employees, and the
existence of multi-state employers make individual state laws
inadequate to address current needs.141 Due to variations in the
protections offered by each state, multi-state employers face the
burden of complying with a multitude of different state rules and
regulations.142 Employees may face uncertainty when applying
for jobs with such employers, or when considering a job
opportunity in another state. An individual might also choose to
forego genetic tests even if the individual lives and works in a
state with a broad genetic discrimination statute because of the
possibility that he may eventually move to another state in which
his genetic information receives less protection. In order to
effectively address the fears that are preventing people from
pursuing genetic tests, as this note argues, uniform federal
regulation is required.
Despite varying degrees of state protection, a large number
138

National Conference of State Legislatures, Genetics Laws and
Legislative Activity (2006), http://www.ncsl.org/programs/health/ genetics/
charts.htm.
139
Id.
140
See id.
141
Hall & Rich, supra note 85, at 253; See also Chorpening, supra note
20, at 1466.
142
See Silvestri, supra note 45, at 421.
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of people remain unprotected under state laws because the
federal Employee Retirement Income Security Act (ERISA)
preempts state laws, thus preventing the protection of people in
self-funded employer plans.143 In short, state laws targeting
genetic discrimination in health insurance only affect insurance
plans outside of this major category. This exception to state
protections may help explain why comparative reports on patient
decisions to decline testing in states with or without genetic
discrimination laws do not follow a pattern correlating to the
existence of such laws.144 This discrepancy apparent from the
reports indicates that state initiatives have had little overall effect
in combating patient fears.
C. Existing Federal Measures Are Insufficient
Contrary to what GINA opponents have suggested, existing
pre-GINA federal legislation falls short of addressing all
concerns at stake in genetic discrimination.145 Examination of
existing laws which might possibly address genetic
discrimination indicates that these laws are not broad enough to
cover all aspects of genetic discrimination and that they fail to
allay the fears currently preventing individuals from undergoing
genetic testing.146 The existing federal provisions include The
Americans with Disabilities Act, Title VII of the Civil Rights
Act, The Health Insurance Portability and Accountability Act,
and Executive Order 13,145.147
143

Employee Retirement Income Security Act of 1974, Pub. L. No. 93406, 88 Stat. 829 (1974); See Hall & Rich, supra note 85, at 253. Nearly
two-thirds of employers in the United States are self-insured. See Sherwin
Chen, Negotiating a Policy of Prudent Science and Proactive Law in the
Brave New World of Genetic Information, 53 HASTINGS L. J. 243, 259
(2001).
144
Hall & Rich, supra note 85, at 253.
145
Silvers & Stein, supra note 22, at 377-78.
146
See Katharine A. Hathaway, Federal Genetic Nondiscrimination
Legislation: The New “Right” and the Race to Protect DNA at the Local,
State, and Federal Level, 52 CATH. U.L. REV. 133, 138-39 (2002).
147
42 U.S.C. § 12112 (2006) (Americans with Disabilities Act); 42
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1. The Americans with Disabilities Act
The Americans with Disabilities Act (ADA) prohibits certain
employers from requesting medical information from potential
employees prior to extending an offer of employment.148 Once
an offer is extended, the employer may request that the potential
employee submit to a medical examination or that he provide
further information.149 Such requests must be uniformly made of
all job applicants.150 Further, the exams or inquiries must be
job-related and consistent with business necessity.151 Once these
conditions are met, the employer may refuse to hire a disabled
employee if reasonable accommodations cannot be made, or if
the presence of the disability is a “direct threat” to others.152
In order for an employee to receive protection from
discrimination under the ADA, the employee must have a
disability as defined by the Act.153 It is unlikely that a genetic
defect, particularly for an individual who has the defect but is
currently asymptomatic, qualifies as a covered disability.154

U.S.C. § 2000e-2(a) (2005) (Title VII of the Civil Rights Act); 29 U.S.C. §
1182(a)(F) (2005) (Health Insurance Portability and Accountability Act);
Exec. Order No. 13,145, 65 Fed. Reg. 6877 (2000).
148
42 U.S.C. § 12112(d)(2)(A) (2006). The Act applies only to
employers with fifteen or more employees. An employer with less than that
amount is not covered. Id. at (5)(A).
149
Id. at (d)(3).
150
Id. at (d)(3)(A).
151
Id. at (d)(4)(A).
152
42 U.S.C. § 12113(b) (2006). The Act defines “direct threat” as a
significant risk to the health or safety of others that cannot be eliminated by
reasonable accommodation. 42 U.S.C. § 12111 (3) (2006).
153
42 U.S.C. § 12112(a) (2006). The ADA defines “disability” as, “(A)
a physical or mental impairment that substantially limits one or more of the
major life activities of such individual; (B) a record of such an impairment;
or (C) being regarded as having such an impairment.” 42 U.S.C. § 12102(2)
(2006). It is unlikely that a genetic predisposition constitutes such a disability.
See Holt, supra note 38, at 469-71.
154
Holt, supra note 38, at 469-71 (discussing impairments that
substantially limit major life activities, and judicial interpretations of
“disability” under the ADA).
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Additionally, individuals who are found to be carriers of a
recessive gene would not receive protection under the Act.155
The EEOC declared in a statement that discrimination based on
genetic testing is covered under the ADA’s third definition of
disability (“being regarded as” having an impairment).156 While
courts may choose to view the EEOC statement as persuasive
when faced with an individual genetic discrimination claim, they
are by no means bound by it.157 Indeed, as demonstrated by
Sutton v. United Airlines, in which the Supreme Court clearly
rejected an EEOC statement regarding another ADA provision,
the EEOC’s interpretation is not always dispositive.158 In
addition, under the “regarded as” definition of disability, courts
have held that the employer must actually be mistaken as to the
disability’s existence.159 Often, an employer may refuse a job
applicant employment in order to avoid the risk that the potential

155

A recessive gene is one that can only be expressed when the
individual has inherited a copy of the recessive gene from both of the
individual’s parents. In a carrier of a recessive gene, only one copy of the
gene is present, and therefore the gene will not be expressed. Such an
individual is not only presently asymptomatic, but also does not sustain any
predisposition for future disability caused by the gene. See Schoonmaker &
Williams, supra note 91, at 4 and n.18. Yet under current federal laws, this
person does not receive any assurances of protection from discrimination. See
Pagnattaro, supra note 110, at 165.
156
EEOC Compliance Manual, Definition of the Term Disability,
§ 902.8(a) (1995).
157
Holt, supra note 38, at 465.
158
Sutton v. United Air Lines, 527 U.S. 471, 482 (1999). The Supreme
Court disagreed with the EEOC interpretation of disability to include
correctable disabilities such as vision impairment. Id.
159
EEOC v. Rockwell Int’l Corp., 60 F. Supp. 2d 791 (N.D. Ill. 1999),
aff’d, 243 F.3d 1012 (7th Cir. 2001) (holding that an employer may reject
applicants who have a propensity to future disability, as long as the employer
is not regarding the applicants as currently disabled); Sutton v. United Air
Lines, 527 U.S. 471, 484-85 (1999) (holding that rejection of applicants
seeking positions as airline pilots because they required corrective lenses for
vision impairments was not barred by the ADA. The employer knew that the
applicants’ vision with corrective lenses in place was not impaired, thus it did
not regard the applicants as currently disabled).
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employee may develop an impairment in the future.160 Thus the
employer has not regarded the applicant as having any current
impairment.161 Accordingly, an individual with a genetic
predisposition to illness who is as yet asymptomatic, may be
barred from bringing suit under the ADA if the employer
refuses to hire the individual in order to avoid a future risk.162
The statutory language of the ADA has contributed to a
relatively narrow interpretation of “disability,” as it cites the
Congressional finding that there are around 43 million
Americans with disabilities.163 An expansion of ADA protected
disabilities to include genetic defects would implicate virtually
every living person,164 undermining the legislative intent to
provide specific protection to the 43 million people currently
classified as disabled.165 Such an inclusion would serve as a
validation of common misperceptions about genetic
information.166 It would lead to the incorrect assumption that
genetic predisposition to disease is in fact an impairment.167
Clearly, this would discourage people from undergoing testing.
Although the Supreme Court has not directly addressed the
issue, the Court has hinted that it will not allow the inclusion of
genetic predispositions in the ADA’s definition of disability.168
160

See Chorpening, supra note 20, at 1453-54; Silvers & Stein, supra
note 22, at 379.
161
Chorpening, supra note 20, at 1454; see also EEOC v. Rockwell, 60
F. Supp. 2d 791 (N.D. Ill. 1999), aff’d, 243 F.3d 1012 (7th Cir. 2001).
162
See Chorpening, supra note 20, at 1454.
163
42 U.S.C. § 12101(a)(1) (2006).
164
Hearings on Genetic Information in the Workplace: Hearing Before
the Senate Comm. on Health, Educ., Labor and Pensions, 106th Cong.
(2000) (testimony of Francis S. Collins, M.D., Ph.D., Director of National
Human
Genome
Research
Institute),
available
at
http://www.genome.gov/10001380.
165
Chorpening, supra note 20, at 1458.
166
See discussion of common misperceptions supra, Part IV.A(2).
167
Holt, supra note 38, at 482.
168
See Bragdon v. Abbot, 524 U.S. 624, 661 (1998) (Rehnquist, C.J.,
concurring in part and dissenting in part) (comparing an individual with
presymptomatic HIV to an individual with a genetic marker for a debilitating
disease, in that neither impairment substantially limits a major life activity, as
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For example, in Chevron U.S.A., Inc. v. Echazabal, the
Supreme Court allowed an extension of the “direct threat to
others” defense to cover threats to oneself as well as to
others.169 The Court upheld the denial of employment to an
individual with a medical condition that might become worse in
the particular work environment.170 Under this expanded
definition of “direct threat,” employers are given a broader
defense to ADA claims that could allow genetic factors to be
considered in hiring decisions.171
Other judicial opinions have demonstrated that the scope of
the ADA does not extend to genetic discrimination. In EEOC v.
Rockwell, a Seventh Circuit case, an employer used predictive
medical tests to screen potential employees for an indicator that
they may develop a particular disability in the future.172 The
applicants were not disabled at the time of the test, nor was
there any guarantee that they would become disabled in the
required for inclusion in the ADA); Sutton v. United Air Lines, 527 U.S.
471, 487 (1999) (holding that correctable myopia may not be considered a
disability under the ADA because such inclusion would encompass too many
people). Both of these opinions cautioned against an over-inclusive definition
of disability under the ADA which could then extend the scope far beyond
the intention of Congress.
169
Chevron U.S.A. Inc. v. Echazabal, 536 U.S. 73, 78-79 (2002).
170
Id. The case involved an individual who was denied employment at
an oil refinery when a post-offer physical exam revealed that he had a liver
condition which could be exacerbated over time. Id. In a post-Echazabal 8th
Circuit case, an insulin-dependent diabetic was denied employment at a
single-pharmacist pharmacy which did not provide for uninterrupted meal
breaks. The court noted that the employer could validly assert a “direct threat
to self” argument. Orr v. Wal-Mart Stores, Inc. 297 F.3d 720 (8th Cir.
2002).
171
See, e.g., Silvers & Stein, supra note 22, at 380. GINA does not
contain a “direct threat” defense, thus broadening the scope of the prohibited
discrimination. See H.R. 1227, 109th Cong. (2005).
172
EEOC v. Rockwell, 60 F. Supp. 2d 791 (N.D. Ill. 1999), aff’d, 243
F.3d 1012 (7th Cir. 2001). Job applicants at the Rockwell International
Corporation were required to undergo nerve conduction tests to detect the
presence of neuropathy, a condition which indicates susceptibility of an
individual to the development of nerve disorders such as carpal tunnel
syndrome. Id. at 1014.
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future.173 Yet the employer rejected applicants who had a
propensity to develop the disability.174 The court found that the
employer did not violate the ADA because the individuals were
not currently disabled, and the employer did not mistakenly
regard them as disabled.175 This decision points toward the
conclusion that genetic discrimination by employers will not be
barred by the ADA, as most employers use genetic information
in a predictive manner, rather than as an indicator of a current
disability.176
2. Title VII of the Civil Rights Act
Title VII of the Civil Rights Act is also an inadequate means
of addressing genetic discrimination because while it prohibits an
employer from basing an employment decision on race, color,
religion, sex, or national origin,177 genetic discrimination does
not readily fit into any of these categories. Although a small
percentage of genetic diseases closely correlate with race, sex,
or national origin, no disease is exclusively linked to these
factors.178
Title VII yields a cause of action for genetic discrimination
only to the extent that an employer chooses to single out job
applicants belonging to a particular Title VII category for a
genetic test. For example, in Norman-Bloodsaw v. Lawrence
Berkeley Laboratory, an employer subjected its black and female
employees to genetic testing for sickle cell trait, syphilis, and
pregnancy.179 The court found that the employees’ claims under
Title VII were valid, as the discriminatory acts of the employer
specifically targeted members of the Title VII categories of race
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Id.
Id.
175
Id. at 1018.
176
See Holt, supra note 38, at 468.
177
42 U.S.C. § 2000e-2(a) (2005).
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179
Norman-Bloodsaw v. Lawrence Berkeley Lab., 135 F.3d 1260, 1265
(9th Cir. 1998).
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and sex.180 Although the genetic discrimination in NormanBloodsaw violated Title VII, much of the fear about genetic
discrimination arises in situations in which employers
discriminate purely on the basis of a genetic factor that
predisposes an individual to illness. Such discrimination does not
correlate to any category of individuals protected under the
existing Title VII. 181
This discrepancy has led some to suggest modification of
Title VII’s categories to include genetic predispositions.182
However, doing so would prevent employers from considering
the potential impact of the genetic predisposition on workplace
safety, including threats to other employees or the general
public.183 Genetic information is unlike race, sex, religion, and
national origin in that it at times raises valid concerns over
public safety and welfare.184 Yet under Title VII, exceptions
such as threat to others or business necessity are not
permitted.185
3. The Health Insurance Portability and Accountability Act
The earliest Congressional attempt to specifically address
genetic discrimination was included in the Health Insurance
Portability and Accountability Act (HIPAA) of 1996.186
Although the legislation contains a specific provision prohibiting
health insurers from denying coverage based on genetic data
about an individual, it does not prevent the insurer from
180
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182
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increasing premiums for groups based on genetic data. 187 The
provisions of HIPAA apply only to group health insurers, and
not to privately held plans.188 Further, the statute does not define
“genetic information,” leaving open the possibility that
information obtained from family medical histories may not be
protected.189 Genetic discrimination in workplace employment
decisions is not addressed by HIPAA.190 The narrow focus of
this legislation does little to persuade people to undergo genetic
testing.191
4. Executive Order 13,145
In an acknowledgment of the need for regulation of the use
of genetic information by employers, President Clinton issued
Executive Order 13,145 in February 2000.192 While this Order
addresses some of the concerns about genetic discrimination, it
applies only in the context of federal employers.193 The Order
can do little to alleviate concerns about discrimination, as it does
not address insurers, and it has no effect on non-federal
employers.194 In addition, the Order provides an exception for
employers who use genetic information “exclusively to assess
whether further medical evaluation is needed to diagnose a
current disease, condition, or disorder.”195 Because the Order
contains no further elucidation of the terms “disease, condition,
or disorder,” employers may be able to retain significant
187
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flexibility in their use of genetic information.196
D. Other (Non-Legislative) Methods of Circumventing the
Fears are Inadequate
Because it is the fear of genetic discrimination, rather than
genetic discrimination itself, that is at the root of this problem,
the use of legislation to combat it must be carefully weighed.
Policy makers need to be aware of the complexities of
influencing a behavioral change in people, and the law should
not be treated “as a simple ‘tool’ for influencing . . . complex
behaviors.”197 Legislating on the basis of existing fears, rather
than existing unwanted activity, presents unique challenges such
as an increased opportunity for unintended consequences and an
increased possibility of unnecessary regulation.198 In addition, it
has been suggested that rather than using legislation to eliminate
all of the risk, educational initiatives should be undertaken with
a focus on “increasing more accurate perception of the risk.”199
Increased public education about the nature of genetic
information
could
effectively
alleviate
fears
and
misconceptions.200 Arguably, implementation of educational
196
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initiatives such as government-sponsored public courses on basic
genetics and improvement of cross-disciplinary communication
between scientists, policy makers, and ethicists, can succeed in
raising public awareness to some extent.201 Furthermore, some
commentators predict that in the future, genetic information will
become such a fundamental part of our lives that people will
inevitably learn how to understand and interpret the information
in an appropriate way.202
However, the current state of scientific understanding in the
general population is extremely low.203 Genetic science has
quickly become a major medical and scientific force, requiring
that policy decisions be made rapidly, leaving little time to carry
out major educational campaigns.204 The most practical solution
to address the current needs of patients may be legislation, or at
the very least, a combination of legislative and educational
initiatives, because the time required to effect a change of public
sentiment is daunting.205 The mere possibility that public
understanding of genetic science will improve in the future does
not preclude the necessity for immediate action to address the
current state of affairs. Further, GINA provides for the
establishment of a committee to evaluate the status of the
implemented legislation after a period of time, at which point
any change in public acceptance of or attitudes toward genetic
testing can be accounted for.206

Education and the Workforce, 108th Congress (2004) (statement of Lawrence
Z. Lorber, Partner, Proskauer Rose, LLP, on behalf of the U.S. Chamber of
Commerce).
201
See Chen, supra note 143, at 257.
202
John C. Fletcher and Dorothy Wertz, Ethics, Law, and Medical
Genetics: After the Human Genome is Mapped, 39 EMORY L. J. 747, 757-58
(1990).
203
See discussion, supra Part IV.A(2).
204
MILLER & KIMMEL, supra note 119, at 237.
205
Hall & Rich, supra note 85, at 255; See also Rose et al., supra note
19, at 150.
206
H.R. 1227, § 208(b) (2005).

3/4/2007 12:41 AM

RIVKA

JOURNAL OF LAW AND POLICY

244

E. The Significance of Genetic Testing for Public Healthcare
and Scientific Research
Because of the significance of genetic testing in two
spheres—that of the advancement of scientific research,207 and
that of the individual’s pursuit of optimal healthcare208—efforts
must be made to address public fears and promote wider public
acceptance of these tests. Indeed, the unique importance of the
tests may be considered yet another distinguishing factor
between genetic discrimination and discrimination based on other
health-related information.209 The unique challenges of using
legislation to target an existing fear are balanced by the unique
importance of genetic testing.210 Whether or not the fear of
genetic discrimination is justified, the fact remains that it is
preventing people from receiving the wide range of benefits of
recent scientific progress.211 This concern speaks to the urgency
of the need for comprehensive federal legislation.212
The individual who undergoes genetic testing may glean
important information leading to better prevention and treatment
options. For example, individuals with genetic mutations that
indicate a high susceptibility to colorectal cancer can follow
recommended guidelines such as undergoing a routine
colonoscopy beginning at age 25.213 A woman who learns that
she is at a high risk for developing breast cancer due to
mutations in her BRCA1 or BRCA2 genes may increase her
screenings or take other preventative measures.214 Other
207
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important applications of genetic test results for healthcare
include characterization of leukemias in order to tailor treatment
options accordingly, and new tests available to determine the
efficiency of specific drugs when used in conjunction with
specific genetic profiles.215
In situations in which the need for genetic testing is crucial,
it is unlikely that fear of genetic discrimination will prevent
people from pursuing it.216 Those who are already exhibiting
signs of a disease are not likely to be deterred from undergoing
a test to confirm a diagnosis.217 In that instance, their
insurability will not significantly change because the carrier will,
at any rate, establish that he has the disease from clinical
reports.218 Additionally, most prenatal genetic testing is not
affected by patient fears of genetic discrimination.219 This is
attributable to the nature of such tests, as they target
spontaneous mutations (which have no implication for other
family members), and a result indicating a severe genetic
abnormality usually leads to termination of the pregnancy.220
In other situations, the deterrent fears may not have any
serious implications for patients. For example, for those who
have a significant family history of a disease, testing is often not
critical because those individuals are already aware that they are
at a high risk and are likely taking preventative measures. For
this group, test results indicating a high propensity for the
disease will change nothing, and the patient, anticipating future
illness, will likely conclude that the test is not worth the risk of
losing their insurance.221 Additionally, some available genetic
years or bilateral mastectomy. Id.
215
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216
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tests are thought to be entirely unnecessary.222 These include
tests for diseases that cannot be prevented, and for which
knowledge of one’s genetic risk will not have any practical
significance.223
The opportunities yielded by the Human Genome Project for
the improvement of public health will remain limited by
scientific investigation into the impact of particular genetic
sequences on human conditions. Accordingly, the National
Human Genome Research Institute has created the Genomes to
Life initiative, which is committed to scientific research into the
clinical significance of the data acquired by the Human Genome
Project.224 However, in order to accomplish this, scientists
depend on the willingness of individuals to undergo genetic
testing for research purposes. This willingness has been
compromised by fears of resultant discrimination in employment
or health insurance.225
Comprehensive federal legislation must be in place in order
to allay the concerns of people contemplating undergoing
testing, whether for purposes of scientific research studies or
personal health, because of the critical importance of genetic
testing in these two spheres.226 A common law evolutionary
model, which allows the common law to evolve over time to
deal with developments not contemplated by existing laws,227
222
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will not suffice in this case. While it is possible that existing
laws might ultimately grow to address some of the concerns
about genetic discrimination, time constraints make this option
unworkable. The passage of time will significantly delay much
needed scientific progress as well as serve to deprive patients of
critical information that could be obtained from genetic testing.
CONCLUSION
The Genetic Information Nondiscrimination Act, as
described above, currently awaits attention in the House of
Representatives.228 Genetic nondiscrimination legislation is
sorely needed, as existing measures do not sufficiently address
the complexities of genetic discrimination. Although the
necessity for legislation has most likely been fueled by general
misunderstanding and/or ignorance of the underlying scientific
bases for genetic testing, the current state of affairs results in
vulnerable populations failing to benefit from potentially lifesaving or life-altering medical advances. Therefore, in the
absence of non-legislative solutions, Congressional legislative
power, as this note argues, must address the issue.
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